Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Completes Sale of TachoSil® to Corza Health
February 1, 2021 GMT
OSAKA, Japan (BUSINESS WIRE) Feb 1, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil ® Fibrin Sealant Patch (“TachoSil ® ”) to Corza Health, Inc. (“Corza”) for €350 million.
ADVERTISEMENT
TachoSil ® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil®, while Takeda maintains ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing & supply agreement, under which it will continue to exclusively manufacture TachoSil